8
views
0
recommends
+1 Recommend
1 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Endometrial Cancer in Brazil: Preparing for the Rising Incidence Translated title: Câncer de endométrio no Brasil: preparando-se para o aumento da incidência

      editorial

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Brazil has a population of over 206 million people.1 It is estimated that there will be 6.22 new cases of endometrial cancer (EC) for every 100,000 Brazilian women in 2018.2 From the estimated 6,000 cases in 2016, GLOBOCAN predicts an increase to 9,372 new cases in 2025 and to 11,963 in 2035.3 Obesity and overweight are well recognized, important risk factors for EC.4 5 6 7 Data from the Brazilian Institute of Geography and Statistics (IBGE, in the Portuguese acronym) show that, in the past 5 decades, the percentage of women > 20 years old who are overweight or obese increased from 29 to 48% and from 8 to 17%, respectively.8 9 10 These trends will only worsen over time, as the IBGE predicts that 38.2% of Brazilian women will be obese by 2022. Older age is another important risk factor, with ∼ 75% of the patients with type I EC (mainly endometrioid histology) being postmenopausal.11 According to the IBGE, the estimated life expectancy in Brazil increased by almost 5 years in the past 15 years, from 73.9 in 2000 to 78.8 years in 2014,12 with an estimated life expectancy of more than 80 years by 2023.13 14 Surgery for EC should be performed by dedicated gynecologic oncologists15 because oncological outcomes improve when EC surgical procedures are performed by high-volume surgeons and in high-volume centers.16 However, other than in the USA, in the UK or in Germany, where gynecologic oncology is a subspecialty of its own that requires 3 + years of formal training, there is no society of gynecologic oncology in Brazil, and subspecialty training of 1 to 2 years is offered in only a few institutions. In addition, > 70% of the Brazilian population are covered by the public health system17 and have difficulty accessing specialized institutions. Therefore, typically, general gynecologists or surgeons perform gyneco-oncologic surgery. Two major randomized trials comparing minimally invasive surgery (MIS) through laparoscopy to traditional open hysterectomy18 19 for the treatment of EC showed the benefits of MIS in terms of morbidity without compromising the oncologic outcomes. Despite a lack of formal data, based on other studies in low and middle-income countries (LMICs),20 it is reasonable to deduct that Brazilian public hospitals lack laparoscopic devices and the capacity to treat all eligible EC patients in the public healthcare system with MIS. Apart from the lack of infrastructure, the availability of MIS also depends on the medical training of the surgeon, which is often insufficient, as discussed above. Another minimally invasive procedure is robotic surgery. The US Food and Drug Administration (FDA) approved robot-assisted management for gynecologic cancer in 2005 and, in 2009, a survey among the members of the US Society of Gynecologic Oncologists (SGO) revealed that 27% of the responders had performed robotic-assisted surgery, and 66% planned to increase their use of it.21 The first Brazilian public robotic platform, the da Vinci Xi Surgical System (Strattner, Rio de Janeiro, RJ, Brazil). was implemented in the Brazilian National Cancer Institute (INCA, in the Portuguese acronym) in 2012. As of June 2018, ∼ 39 robotic systems had been installed in Brazil. It is worth emphasizing that only 4 of these 39 robotic platforms were operating in public hospitals.22 Most EC cases are diagnosed at an early stage, and international guidelines recommend adjuvant pelvic radiation or brachytherapy, depending on the risk of recurrence.23 24 In 2013, the INCA and the Brazilian Society of Radiotherapy (SBR, in the Portuguese acronym) estimated a shortage of 135 machines and ∼ 90,000 patients per year not receiving radiation therapy despite its indication.25 Overall, the public healthcare sector covers only 69.5% of the need for radiotherapy in Brazil, and there are some states with coverage of less than 50%.25 Based on recommendations of the Brazilian government in 2014 (1 teletherapy machine per 500,000 inhabitants),26 ∼ 412 machines would be needed to cover the entire Brazilian population of 206 million. However, as of 2016, only 292 specialized radiotherapy centers were available for the whole country, of which 223 were in the public system.27 This deficit translates into lack of treatment and into an overload of the institutions that have radiotherapy machines, resulting in a median delay in the initiation of treatment of 113.4 days (almost 4 months).25 In a recent report, it was estimated that 111,432 patients who required radiotherapy in 2016 did not receive this treatment, and that over 5,000 deaths would probably have been prevented in the cases of the most common cancer types if radiotherapy access were universal in the Brazilian Public Health System (SUS, in the Portuguese acronym).28 29 There is room for improvement in three major areas when it comes to EC care and control in Brazil: Increase the number of radiotherapy machines. In 2012,27 the federal government planned to increase its radiotherapy services, adding 80 linear accelerators by 2015 (32 machines to centers with existing radiotherapy services, and 48 to new centers).30 As of April 2017, however, the last bulletin from the Ministry of Health showed that only 10 centers have initiated this expansion, only 1 machine has been installed, and 6 centers had subsequently been excluded from the plan.30 With a timeframe of ∼ 30 months between the building of the bunker and the beginning of operations of the system, it is urgent to make progress as soon as possible. Improve training and expertise of gyneco-oncologists. It is necessary to expand training programs for radio-oncologists and to promote specialized training in gynecologic oncology, specifically in performing MIS. Oncological surgeons in Brazil have expressed willingness to create a gynecologic oncology subspecialty in the country, which would certainly improve clinical readiness to deal with EC cases. Support prevention strategies. Recently, the INCA launched national recommendations on healthy nutrition and exercise to educate the population about the risks of a sedentary lifestyle and poor eating habits and their relation to cancer.31 Concerted efforts now need to be made to ensure that these measures of primary prevention reach the general public. The incidence of EC is rising in both high and middle-income countries due to an increase in Westernized lifestyles, to the rates of overweight and obesity, and to a higher life expectancy. Brazil will face a sharp increase in EC cases in the next decade, which will exacerbate the current shortages and barriers in the treatment of EC. It is therefore imperative to implement EC prevention policies, improve radiotherapy resources, and augment equitable patient access to specialized and well-equipped cancer centers with trained professionals.

          Related collections

          Most cited references18

          • Record: found
          • Abstract: found
          • Article: not found

          Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies.

          Excess bodyweight, expressed as increased body-mass index (BMI), is associated with the risk of some common adult cancers. We did a systematic review and meta-analysis to assess the strength of associations between BMI and different sites of cancer and to investigate differences in these associations between sex and ethnic groups. We did electronic searches on Medline and Embase (1966 to November 2007), and searched reports to identify prospective studies of incident cases of 20 cancer types. We did random-effects meta-analyses and meta-regressions of study-specific incremental estimates to determine the risk of cancer associated with a 5 kg/m2 increase in BMI. We analysed 221 datasets (141 articles), including 282,137 incident cases. In men, a 5 kg/m2 increase in BMI was strongly associated with oesophageal adenocarcinoma (RR 1.52, p<0.0001) and with thyroid (1.33, p=0.02), colon (1.24, p<0.0001), and renal (1.24, p <0.0001) cancers. In women, we recorded strong associations between a 5 kg/m2 increase in BMI and endometrial (1.59, p<0.0001), gallbladder (1.59, p=0.04), oesophageal adenocarcinoma (1.51, p<0.0001), and renal (1.34, p<0.0001) cancers. We noted weaker positive associations (RR <1.20) between increased BMI and rectal cancer and malignant melanoma in men; postmenopausal breast, pancreatic, thyroid, and colon cancers in women; and leukaemia, multiple myeloma, and non-Hodgkin lymphoma in both sexes. Associations were stronger in men than in women for colon (p<0.0001) cancer. Associations were generally similar in studies from North America, Europe and Australia, and the Asia-Pacific region, but we recorded stronger associations in Asia-Pacific populations between increased BMI and premenopausal (p=0.009) and postmenopausal (p=0.06) breast cancers. Increased BMI is associated with increased risk of common and less common malignancies. For some cancer types, associations differ between sexes and populations of different ethnic origins. These epidemiological observations should inform the exploration of biological mechanisms that link obesity with cancer.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer: diagnosis, treatment and follow-up.

            The first joint European Society for Medical Oncology (ESMO), European SocieTy for Radiotherapy & Oncology (ESTRO) and European Society of Gynaecological Oncology (ESGO) consensus conference on endometrial cancer was held on 11-13 December 2014 in Milan, Italy, and comprised a multidisciplinary panel of 40 leading experts in the management of endometrial cancer. Before the conference, the expert panel prepared three clinically relevant questions about endometrial cancer relating to the following four areas: prevention and screening, surgery, adjuvant treatment and advanced and recurrent disease. All relevant scientific literature, as identified by the experts, was reviewed in advance. During the consensus conference, the panel developed recommendations for each specific question and a consensus was reached. Results of this consensus conference, together with a summary of evidence supporting each recommendation, are detailed in this article. All participants have approved this final article.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Cancer incidence and mortality in relation to body mass index in the Million Women Study: cohort study.

              To examine the relation between body mass index (kg/m2) and cancer incidence and mortality. Prospective cohort study. 1.2 million UK women recruited into the Million Women Study, aged 50-64 during 1996-2001, and followed up, on average, for 5.4 years for cancer incidence and 7.0 years for cancer mortality. Relative risks of incidence and mortality for all cancers, and for 17 specific types of cancer, according to body mass index, adjusted for age, geographical region, socioeconomic status, age at first birth, parity, smoking status, alcohol intake, physical activity, years since menopause, and use of hormone replacement therapy. 45,037 incident cancers and 17 203 deaths from cancer occurred over the follow-up period. Increasing body mass index was associated with an increased incidence of endometrial cancer (trend in relative risk per 10 units=2.89, 95% confidence interval 2.62 to 3.18), adenocarcinoma of the oesophagus (2.38, 1.59 to 3.56), kidney cancer (1.53, 1.27 to 1.84), leukaemia (1.50, 1.23 to 1.83), multiple myeloma (1.31, 1.04 to 1.65), pancreatic cancer (1.24, 1.03 to 1.48), non-Hodgkin's lymphoma (1.17, 1.03 to 1.34), ovarian cancer (1.14, 1.03 to 1.27), all cancers combined (1.12, 1.09 to 1.14), breast cancer in postmenopausal women (1.40, 1.31 to 1.49) and colorectal cancer in premenopausal women (1.61, 1.05 to 2.48). In general, the relation between body mass index and mortality was similar to that for incidence. For colorectal cancer, malignant melanoma, breast cancer, and endometrial cancer, the effect of body mass index on risk differed significantly according to menopausal status. Increasing body mass index is associated with a significant increase in the risk of cancer for 10 out of 17 specific types examined. Among postmenopausal women in the UK, 5% of all cancers (about 6000 annually) are attributable to being overweight or obese. For endometrial cancer and adenocarcinoma of the oesophagus, body mass index represents a major modifiable risk factor; about half of all cases in postmenopausal women are attributable to overweight or obesity.
                Bookmark

                Author and article information

                Journal
                Rev Bras Ginecol Obstet
                Rev Bras Ginecol Obstet
                10.1055/s-00030576
                RBGO Gynecology & Obstetrics
                Thieme Revinter Publicações Ltda (Rio de Janeiro, Brazil )
                0100-7203
                1806-9339
                October 2018
                1 October 2018
                : 40
                : 10
                : 577-579
                Affiliations
                [1 ]Global Cancer Institute, Boston, Masachussets, United States
                [2 ]Americas Centro de Oncologia Integrado, Rio de Janeiro, RJ, Brazil
                [3 ]Instituto Nacional de Câncer, Rio de Janeiro, RJ, Brazil
                [4 ]Universidade Federal de Minas Gerais, Belo Horizonte, MG, Brazil
                [5 ]Wilhelminen Hospital, Vienna, Austria
                Author notes
                Address for correspondence Eduardo Paulino, MD Rua Equador 831, 2020-410, Rio de Janeiro, RJBrazil dudupaulino@ 123456globo.com
                Article
                4009ed
                10.1055/s-0038-1673644
                10418351
                30352454
                a6983a46-3672-4a0e-ac02-cf5dc1c940a0

                This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

                History
                Categories
                Editorial

                Comments

                Comment on this article